查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1454796

无细胞胎儿 DNA 检测市场：依产品类型、最终用户、地区（北美、欧洲、亚太地区、拉丁美洲、中东非洲）、规模、占有率、成长、趋势进行的全球产业分析，2023-2030 年预测

Cell-free Fetal DNA Testing Market by Product Type, End-Users, and Geography (North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa): Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2030
出版日期: | 出版商: Persistence Market Research | 英文 267 Pages | 商品交期: 2-5个工作天内

价格
简介目录

持久性市场研究对无细胞胎儿 DNA 检测市场进行了深入分析，并提供了有关全球状况的综合报告。 该报告提供了有关市场动态、趋势、机会和课题的重要见解，并详细概述了市场结构。 研究报告预测了 2023 年至 2030 年无细胞胎儿 DNA 检测市场的预期成长轨迹，并包含独家数据和统计数据。

全球无细胞胎儿 DNA 检测市场预计将以 10% 的复合年增长率成长，估值从 2023 年的 15 亿美元增至 2030 年的 29 亿美元。

关键见解

  • 无细胞胎儿 DNA 检测市场规模（2023 年）：15 亿美元
  • 预计市场价值（2030 年）：29 亿美元
  • 全球市场成长率（2023-2030 年复合年增长率）：10.0%
  • 过去的市场成长率（2018-2022 年复合年增长率）：9.0%

胎儿游离DNA检测市场-调查范围

一种称为无细胞胎儿 DNA 检测 (cffDNA) 的创新产前筛检透过检查母亲血液中存在的胎儿 DNA 片段，彻底改变了胎儿基因分析。 这项技术消除了羊膜穿刺等侵入性手术的需要，并提供了无风险的重要遗传见解。 CffDNA 检测确保以更安全的方式评估胎儿的健康状况，特别是在检测唐氏症等染色体异常方面。

在产前诊断的动态格局中，CFFDNA 检测市场呈现显着成长。 推动这一扩张的因素包括公众意识的提高、技术进步以及对早期、非侵入性产前筛检的关注。 对准确可靠的产前基因检测日益增长的需求正在推动这一成长轨迹。 其结果是创造出创新的商业机会，满足世界各地孕妇不断变化的需求。

市场成长促进因素

基因组技术的进步，尤其是下一代定序 (NGS)，正在推动无细胞胎儿 DNA 检测市场的成长。 NGS 提高了准确性和效率，使其更容易被更广泛的孕妇使用。 母亲年龄的增加和对产前筛检选择的认识不断提高等因素进一步促进了市场的扩张。 对非侵入性早期检测方法的需求持续成长，刺激了产前诊断市场的成长和技术创新。

市场限制因子

儘管取得了重大进展，但无细胞胎儿 DNA 检测的商业扩张仍受到监管课题和伦理考虑的严重阻碍。 由于旨在确保这些测试的准确性和可靠性的严格规定，以及对遗传讯息潜在滥用的道德担忧，行业利益相关者遇到了障碍。 应对复杂的监管环境并解决与产前基因检测相关的道德困境对于促进这些先进技术的持续成长和传播至关重要。

市场机会

无细胞胎儿 DNA 检测领域的扩展对该行业来说是一个充满希望的机会。 然而，由于监管合规性和道德问题，课题仍然存在。 有效的市场渗透策略，包括与当地医疗保健提供者的合作伙伴关係和文化适应性，对于成功至关重要。 将产前基因检测与全面的妇女健康计划相结合可以改善患者的治疗结果和获得护理的机会。 教育差异和获取机会的差异仍然是需要解决的障碍，以确保公平地获得这些创新筛检技术。

本报告涵盖的主要问题

  • 推动无细胞胎儿 DNA 检测市场成长的因素有哪些？
  • 基因组技术的哪些进步有助于扩大产前基因检测？
  • 影响无细胞胎儿 DNA 检测商业化的监管课题和伦理考量有哪些？
  • 企业如何有效进入新兴的产前基因检测市场？
  • 将胎儿游离 DNA 检测纳入综合女性健康计画有哪些潜在好处？

目录

第 1 章执行摘要

第二章市场概述

  • 市场范围与定义
  • 市场动态
    • 促进因素
    • 抑制因素
    • 机会
    • 作业
    • 主要趋势
  • 测试类型生命週期分析
  • 无细胞胎儿 DNA 检测市场：价值链
    • 原料供应商名单
    • 製造商列表
    • 销售代理商名单
    • 申请列表
    • 获利能力分析
  • 波特五力分析
  • 地缘政治紧张局势：对市场的影响
  • 宏观经济因素
    • 世界产业展望
    • 世界 GDP 成长率的前景
    • 全球母公司市场概览
  • 预测因子 - 相关性和影响
  • 监管与科技环境

第三章全球胎儿游离DNA检测市场展望：实际结果（2018-2022年）与预测（2023-2030年）

  • 主要亮点
    • 市场容量（单位）预测
    • 市场规模及年成长率
    • 绝对的获利机会
  • 市场规模（万美元）分析与预测
    • 过去的市场规模分析，2013-2016 年
    • 2018-2026 年目前市场规模预测
  • 全球游离胎儿 DNA 检测市场前景：检测类型
    • 简介/主要发现
    • 2018 年至 2022 年依测试类型划分的历史市场规模（百万美元）和数量（单位）分析
    • 2023-2030 年依测试类型划分的当前市场规模（百万美元）和预测数量（单位）
      • 染色体数目异常检测
      • 性别测试
      • 父系遗传性疾病
  • 市场吸引力分析：最终用户

第 4 章全球胎儿游离 DNA 检测市场前景：地区

  • 主要亮点
  • 2018-2022 年依地区历史市场规模（百万美元）及销售量（单位）分析
  • 2023-2030 年依地区划分的当前市场规模（百万美元）和预测销售（单位）
    • 北美
    • 欧洲
    • 东亚
    • 南亚和大洋洲
    • 拉丁美洲
    • 中东和非洲 (MEA)
  • 市场吸引力分析：地区

第五章北美胎儿游离DNA检测市场展望：实际结果（2018-2022年）与预测（2023-2030年）

  • 主要亮点
  • 价格分析
  • 2018-2022 年过去的市场规模（10,000 美元）和市场销售（单位）分析
    • 依国家/地区
    • 依测试类型
    • 依最终用户
  • 2023-2030 年依国家/地区划分的当前市场规模（百万美元）和销售（单位）预测
    • 美国
    • 加拿大
  • 2023-2030 年依测试类型划分的当前市场规模（百万美元）和预测数量（单位）
    • 染色体数目异常检测
    • 性别测试
    • 父系遗传性疾病
  • 市场吸引力分析

第 6 章欧洲无细胞胎儿 DNA 检测市场展望：实际（2018-2022 年）与预测（2023-2030 年）

  • 主要亮点
  • 价格分析
  • 2018-2022 年过去的市场规模（10,000 美元）和市场销售（单位）分析
    • 依国家/地区
    • 依测试类型
    • 依最终用户
  • 2023-2030 年依国家/地区划分的当前市场规模（百万美元）和销售（单位）预测
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 土耳其
    • 欧洲其他地区
  • 2023-2030 年依测试类型划分的当前市场规模（百万美元）和预测数量（单位）
    • 染色体数目异常检测
    • 性别测试
    • 父系遗传性疾病
  • 市场吸引力分析

第七章东亚无细胞胎儿DNA检测市场展望：实际（2018-2022年）与预测（2023-2030年）

  • 主要亮点
  • 价格分析
  • 2018-2022 年过去的市场规模（10,000 美元）和市场销售（单位）分析
    • 依国家/地区
    • 依测试类型
    • 依最终用户
  • 2023-2030 年依国家/地区划分的当前市场规模（百万美元）和销售（单位）预测
    • 中国
    • 日本
    • 韩国
  • 2023-2030 年依测试类型划分的当前市场规模（百万美元）和预测数量（单位）
    • 染色体数目异常检测
    • 性别测试
    • 父系遗传性疾病
  • 市场吸引力分析

第 8 章南亚和大洋洲无细胞胎儿 DNA 检测市场展望：实际（2018-2022 年）和预测（2023-2030 年）

  • 主要亮点
  • 价格分析
  • 2018-2022 年过去的市场规模（10,000 美元）和市场销售（单位）分析
    • 依国家/地区
    • 依测试类型
    • 依最终用户
  • 2023-2030 年依国家/地区划分的当前市场规模（百万美元）和销售（单位）预测
    • 印度
    • 东南亚
    • 纽西兰
    • 南亚和大洋洲其他地区
  • 2023-2030 年依测试类型划分的当前市场规模（百万美元）和预测数量（单位）
    • 染色体数目异常检测
    • 性别测试
    • 父系遗传性疾病
  • 市场吸引力分析

第 9 章拉丁美洲无细胞胎儿 DNA 检测市场展望：实际（2018-2022 年）和预测（2023-2030 年）

  • 主要亮点
  • 价格分析
  • 2018-2022 年过去的市场规模（10,000 美元）和市场销售（单位）分析
    • 依国家/地区
    • 依测试类型
    • 依最终用户
  • 2023-2030 年依国家/地区划分的当前市场规模（百万美元）和销售（单位）预测
    • 巴西
    • 墨西哥
    • 其他拉丁美洲地区
  • 2023-2030 年依测试类型划分的当前市场规模（百万美元）和预测数量（单位）
    • 染色体数目异常检测
    • 性别测试
    • 父系遗传性疾病
  • 市场吸引力分析

第 10 章中东和非洲的无细胞胎儿 DNA 测试市场前景：实际（2018-2022）和预测（2023-2030）

  • 主要亮点
  • 价格分析
  • 2018-2022 年过去的市场规模（10,000 美元）和市场销售（单位）分析
    • 依国家/地区
    • 依测试类型
    • 依最终用户
  • 2023-2030 年依国家/地区划分的当前市场规模（百万美元）和销售（单位）预测
    • 海湾合作委员会
    • 埃及
    • 南非
    • 北非
    • 其他中东和非洲地区
  • 2023-2030 年依测试类型划分的当前市场规模（百万美元）和预测数量（单位）
    • 染色体数目异常检测
    • 性别测试
    • 父系遗传性疾病
  • 市场吸引力分析

第十一章竞争态势

  • 2022 年市占率分析
  • 市场结构
    • 依市场划分的竞争强度图
    • 竞争对手仪表板
    • 表观测试类型容量
  • 公司简介（详细资料 - 概述、财务状况、策略、近期发展）
    • Sequenom Laboratories
    • Illumina, Inc.
    • Ariosa Diagnostics
    • Arup Laboratories
    • The Fetal Medicine Center
    • Apollo Path labs

第12章附录

  • 调查方法
  • 调查假设
  • 首字母缩写词和缩写词
简介目录
Product Code: PMRREP33956

Persistence Market Research has recently conducted an in-depth analysis of the Cell-free Fetal DNA Testing Market, providing a comprehensive report on the global landscape. This report offers key insights into market dynamics, trends, opportunities, and challenges, offering a detailed overview of the market structure. The research publication presents exclusive data and statistics, projecting the anticipated growth trajectory of the Cell-free Fetal DNA Testing Market from 2023 to 2030.

The worldwide market for cell-free fetal DNA testing is projected to grow at a compound annual growth rate (CAGR) of 10%, reaching a valuation of US$2.9 billion by 2030, up from US$1.5 billion in 2023.

Key Insights:

  • Cell-free Fetal DNA Testing Market Size (2023E): US$1.5 Bn
  • Projected Market Value (2030F): US$2.9 Bn
  • Global Market Growth Rate (CAGR 2023 to 2030): 10.0%
  • Historical Market Growth Rate (CAGR 2018 to 2022): 9.0%

Cell-free Fetal DNA Testing Market - Report Scope

Innovative prenatal screening, known as cell-free fetal DNA testing (cffDNA), revolutionizes genetic analysis of unborn babies by examining fetal DNA fragments present in the mother's blood. This technique eliminates the need for invasive procedures like amniocentesis, providing crucial genetic insights without risks. CffDNA testing ensures a safer means of assessing fetal health, particularly in detecting chromosomal abnormalities such as Down syndrome.

Amidst the dynamic landscape of prenatal diagnostics, the market for cffDNA testing is witnessing substantial growth. Factors driving this expansion include heightened public awareness, advancements in technology, and a focus on early, non-invasive prenatal screening. The rising demand for accurate and reliable prenatal genetic testing fuels this growth trajectory. Consequently, there arises an opportunity for businesses to innovate and cater to the evolving needs of expectant parents worldwide.

Market Growth Drivers

Advancements in genomic technologies, particularly next-generation sequencing (NGS), are driving growth in the cell-free fetal DNA testing market. NGS enhances accuracy and efficiency, making it feasible for a broader range of expectant parents. Factors such as increasing maternal age and greater awareness of prenatal screening options further contribute to market expansion. The demand for non-invasive, early detection methods continues to grow, stimulating both market growth and technological innovation in prenatal diagnostics.

Market Restraints

Despite significant progress, the commercial expansion of cell-free fetal DNA testing is significantly impeded by regulatory challenges and ethical considerations. Industry stakeholders encounter hurdles due to stringent regulations aimed at ensuring the accuracy and reliability of these tests, as well as ethical concerns regarding the potential misuse of genetic information. To foster the continued growth and widespread adoption of these advanced technologies, navigating complex regulatory landscapes and addressing ethical dilemmas associated with prenatal genetic testing will be imperative.

Opportunities

Global expansion of cell-free fetal DNA testing presents a promising opportunity for the industry. However, challenges persist due to regulatory compliance and ethical concerns. Effective market penetration strategies, including partnerships with regional healthcare providers and cultural adaptability, are crucial for success. Combining prenatal genetic testing with comprehensive women's health programs can enhance patient outcomes and access to care. Educational gaps and disparities in accessibility remain obstacles that need to be addressed to ensure equitable access to these innovative screening technologies.

Key Questions Answered in Report::

  • What are the factors driving the growth of the cell-free fetal DNA testing market?
  • What advancements in genomic technologies have contributed to the expansion of prenatal genetic testing?
  • What regulatory challenges and ethical considerations impact the commercialization of cell-free fetal DNA testing?
  • How can businesses effectively penetrate emerging markets for prenatal genetic testing?
  • What are the potential benefits of integrating cell-free fetal DNA testing into comprehensive women's health programs?

Competitive Intelligence and Business Strategy

The market for cell-free fetal DNA testing is fiercely competitive, with established giants like Sequenom Laboratories and newcomers like Apollo Path Labs vying for dominance. Strategic partnerships, robust R&D, and mergers and acquisitions drive innovation and market share expansion. Emerging specialty firms contribute to diversity and innovation, challenging established players and fueling healthy competition. Dynamic market dynamics and technological advancements shape the competitive landscape, offering both opportunities and challenges for industry participants.

Key Companies Profiled

  • Sequenom Laboratories
  • Illumina, Inc.
  • Ariosa Diagnostics
  • Arup Laboratories
  • The Fetal Medicine Center
  • Apollo Path labs

Cell-free Fetal DNA Testing Market Segmentation

By Test Type:

  • Detection of Abnormal Chromosome Number
  • Gender Testing
  • Paternally Inherited Disorders

By Region:

  • North America
  • Europe
  • East Asia
  • South Asia & Oceania
  • Latin America
  • Middle East & Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Cell-free Fetal DNA Testing Market Snapshot, 2023 and 2030
  • 1.2. Market Opportunity Assessment, 2023 - 2030, US$ Mn
  • 1.3. Key Market Trends
  • 1.4. Future Market Projections
  • 1.5. Premium Market Insights
  • 1.6. Industry Developments and Key Market Events
  • 1.7. PMR Analysis and Recommendations

2. Market Overview

  • 2.1. Market Scope and Definition
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Opportunity
    • 2.2.4. Challenges
    • 2.2.5. Key Trends
  • 2.3. Test Type Lifecycle Analysis
  • 2.4. Cell-free Fetal DNA Testing Market: Value Chain
    • 2.4.1. List of Raw Material Supplier
    • 2.4.2. List of Manufacturers
    • 2.4.3. List of Distributors
    • 2.4.4. List of Applications
    • 2.4.5. Profitability Analysis
  • 2.5. Porter Five Force's Analysis
  • 2.6. Geopolitical Tensions: Market Impact
  • 2.7. Macro-Economic Factors
    • 2.7.1. Global Sectorial Outlook
    • 2.7.2. Global GDP Growth Outlook
    • 2.7.3. Global Parent Market Overview
  • 2.8. Forecast Factors - Relevance and Impact
  • 2.9. Regulatory and Technology Landscape

3. Global Cell-free Fetal DNA Testing Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

  • 3.1. Key Highlights
    • 3.1.1. Market Volume (Units) Projections
    • 3.1.2. Market Size and Y-o-Y Growth
    • 3.1.3. Absolute $ Opportunity
  • 3.2. Market Size (US$ Mn) Analysis and Forecast
    • 3.2.1. Historical Market Size Analysis, 2013-2016
    • 3.2.2. Current Market Size Forecast, 2018-2026
  • 3.3. Global Cell-free Fetal DNA Testing Market Outlook: Test Type
    • 3.3.1. Introduction / Key Findings
    • 3.3.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Test Type, 2018 - 2022
    • 3.3.3. Current Market Size (US$ Mn) and Volume (Units) Forecast By Test Type, 2023 - 2030
      • 3.3.3.1. Detection of Abnormal Chromosome Number
      • 3.3.3.2. Gender Testing
      • 3.3.3.3. Paternally Inherited Disorders
  • 3.4. Market Attractiveness Analysis: End User

4. Global Cell-free Fetal DNA Testing Market Outlook: Region

  • 4.1. Key Highlights
  • 4.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Region, 2018 - 2022
  • 4.3. Current Market Size (US$ Mn) and Volume (Units) Forecast By Region, 2023 - 2030
    • 4.3.1. North America
    • 4.3.2. Europe
    • 4.3.3. East Asia
    • 4.3.4. South Asia and Oceania
    • 4.3.5. Latin America
    • 4.3.6. Middle East & Africa (MEA)
  • 4.4. Market Attractiveness Analysis: Region

5. North America Cell-free Fetal DNA Testing Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

  • 5.1. Key Highlights
  • 5.2. Pricing Analysis
  • 5.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
    • 5.3.1. By Country
    • 5.3.2. By Test Type
    • 5.3.3. By End User
  • 5.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
    • 5.4.1. U.S.
    • 5.4.2. Canada
  • 5.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Test Type, 2023 - 2030
    • 5.5.1. Detection of Abnormal Chromosome Number
    • 5.5.2. Gender Testing
    • 5.5.3. Paternally Inherited Disorders
  • 5.6. Market Attractiveness Analysis

6. Europe Cell-free Fetal DNA Testing Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

  • 6.1. Key Highlights
  • 6.2. Pricing Analysis
  • 6.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
    • 6.3.1. By Country
    • 6.3.2. By Test Type
    • 6.3.3. By End User
  • 6.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
    • 6.4.1. Germany
    • 6.4.2. France
    • 6.4.3. U.K.
    • 6.4.4. Italy
    • 6.4.5. Spain
    • 6.4.6. Russia
    • 6.4.7. T rkiye
    • 6.4.8. Rest of Europe
  • 6.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Test Type, 2023 - 2030
    • 6.5.1. Detection of Abnormal Chromosome Number
    • 6.5.2. Gender Testing
    • 6.5.3. Paternally Inherited Disorders
  • 6.6. Market Attractiveness Analysis

7. East Asia Cell-free Fetal DNA Testing Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

  • 7.1. Key Highlights
  • 7.2. Pricing Analysis
  • 7.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
    • 7.3.1. By Country
    • 7.3.2. By Test Type
    • 7.3.3. By End User
  • 7.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
    • 7.4.1. China
    • 7.4.2. Japan
    • 7.4.3. South Korea
  • 7.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Test Type, 2023 - 2030
    • 7.5.1. Detection of Abnormal Chromosome Number
    • 7.5.2. Gender Testing
    • 7.5.3. Paternally Inherited Disorders
  • 7.6. Market Attractiveness Analysis

8. South Asia & Oceania Cell-free Fetal DNA Testing Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

  • 8.1. Key Highlights
  • 8.2. Pricing Analysis
  • 8.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
    • 8.3.1. By Country
    • 8.3.2. By Test Type
    • 8.3.3. By End User
  • 8.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
    • 8.4.1. India
    • 8.4.2. Southeast Asia
    • 8.4.3. ANZ
    • 8.4.4. Rest of South Asia & Oceania
  • 8.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Test Type, 2023 - 2030
    • 8.5.1. Detection of Abnormal Chromosome Number
    • 8.5.2. Gender Testing
    • 8.5.3. Paternally Inherited Disorders
  • 8.6. Market Attractiveness Analysis

9. Latin America Cell-free Fetal DNA Testing Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

  • 9.1. Key Highlights
  • 9.2. Pricing Analysis
  • 9.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
    • 9.3.1. By Country
    • 9.3.2. By Test Type
    • 9.3.3. By End User
  • 9.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
    • 9.4.1. Brazil
    • 9.4.2. Mexico
    • 9.4.3. Rest of Latin America
  • 9.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Test Type, 2023 - 2030
    • 9.5.1. Detection of Abnormal Chromosome Number
    • 9.5.2. Gender Testing
    • 9.5.3. Paternally Inherited Disorders
  • 9.6. Market Attractiveness Analysis

10. Middle East & Africa Cell-free Fetal DNA Testing Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

  • 10.1. Key Highlights
  • 10.2. Pricing Analysis
  • 10.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
    • 10.3.1. By Country
    • 10.3.2. By Test Type
    • 10.3.3. By End User
  • 10.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
    • 10.4.1. GCC
    • 10.4.2. Egypt
    • 10.4.3. South Africa
    • 10.4.4. Northern Africa
    • 10.4.5. Rest of Middle East & Africa
  • 10.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Test Type, 2023 - 2030
    • 10.5.1. Detection of Abnormal Chromosome Number
    • 10.5.2. Gender Testing
    • 10.5.3. Paternally Inherited Disorders
  • 10.6. Market Attractiveness Analysis

11. Competition Landscape

  • 11.1. Market Share Analysis, 2022
  • 11.2. Market Structure
    • 11.2.1. Competition Intensity Mapping By Market
    • 11.2.2. Competition Dashboard
    • 11.2.3. Apparent Test Type Capacity
  • 11.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
    • 11.3.1. Sequenom Laboratories
      • 11.3.1.1. Overview
      • 11.3.1.2. Segments and Test Type
      • 11.3.1.3. Key Financials
      • 11.3.1.4. Market Developments
      • 11.3.1.5. Market Strategy
    • 11.3.2. Illumina, Inc.
      • 11.3.2.1. Overview
      • 11.3.2.2. Segments and Test Type
      • 11.3.2.3. Key Financials
      • 11.3.2.4. Market Developments
      • 11.3.2.5. Market Strategy
    • 11.3.3. Ariosa Diagnostics
      • 11.3.3.1. Overview
      • 11.3.3.2. Segments and Test Type
      • 11.3.3.3. Key Financials
      • 11.3.3.4. Market Developments
      • 11.3.3.5. Market Strategy
    • 11.3.4. Arup Laboratories
      • 11.3.4.1. Overview
      • 11.3.4.2. Segments and Test Type
      • 11.3.4.3. Key Financials
      • 11.3.4.4. Market Developments
      • 11.3.4.5. Market Strategy
    • 11.3.5. The Fetal Medicine Center
      • 11.3.5.1. Overview
      • 11.3.5.2. Segments and Test Type
      • 11.3.5.3. Key Financials
      • 11.3.5.4. Market Developments
      • 11.3.5.5. Market Strategy
    • 11.3.6. Apollo Path labs
      • 11.3.6.1. Overview
      • 11.3.6.2. Segments and Test Type
      • 11.3.6.3. Key Financials
      • 11.3.6.4. Market Developments
      • 11.3.6.5. Market Strategy

12. Appendix

  • 12.1. Research Methodology
  • 12.2. Research Assumptions
  • 12.3. Acronyms and Abbreviations